Welcome to the World ADC media hub. Here you will find exclusive insights from our expert speakers, past presentations and articles plus much more.
Email adc@hansonwade.com if you submit for approval content that you wish to share.
NEWLY ADDED!
CDMO's in the Preclinical ADC Space: A Benchmarking Study
Antibody-Drug Conjugates (ADC) have progressed a long way as a modality in recent times, culminating in a flurry of new drug approvals over the past couple of years. However, despite this progress, there is little in the public domain detailing how service providers are used in this space, particularly for assets at the preclinical stage where the announcement of partnerships is rare.
At Hanson Wade Intelligence, we sought to shed light on this under-represented area. We carried out a survey of 51 preclinical ADC developers, as well as carrying out in-depth interviews to support the sentiment uncovered in the survey.
So whether you are a developer, a service provider, or an observer of this space, this report will add to your understanding and provide some well-needed clarity to the preclinical ADC space. We uncover the major players, the importance of company size and molecule toxicity, and the traits that developers consider the most important when outsourcing their preclinical ADC assets.
By Hanson Wade Market Research
Newly Added!
An Exclusive Speaker Interview With…
Radek Spisek, Chief Executive Officer, SOTIO
The Rise and Rise of mRNA
By the Medicine Maker, World ADC San Diego Media Partner
An Exclusive Speaker Interview With Byondis:
- Ruud Coumans, Project Leader, Antibody-Drug Conjugates
- Patrick Groothuis, Principal Scientist, In Vivo Pharmacology, Toxicology, Drug Metabolism & Pharmacokinetic
- Evelyn Van Den Tweel, Project Leader, Clinical Development
An Exclusive Speaker Interview With:
Amy Peterson, Executive Vice President & Chief Development Officer, CytomX
ADC Magazine
Goodwin Biotechnology Poster
ADC London Post Event Report
Speaker Interview
Antibody Drug Conjugates Clinical E-Book
Abzena announces 20m$ investment
2017 Post Event Report
Past Presentations
ADCs with two bundles of chelator groups of
radionuclides for theranostic applications
Assessing Phase 1 Interim Data of
MORAb-202, a Folate Receptor
Alpha-Targeted Antibody-Drug
Conjugate
Toshimitsu Uenaka.
Linker Design: Why so complex? – GNF
Bernhard Geierstanger
Clinical Development of ADCs: ARX788, a Her2-targeting ADC as an Example – Ambrx
Yong-jiang Hei, M.D., Ph.D.
Novel Warheads for Targeted Therapies of Cancer - pro-PBDs: from Design to Clinical Candidates
Iontcho R. Vlahov, PhD
VP of Discovery Chemistry
Endocyte, Inc., West Lafayette, IN, USA
